REGENERON PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
REGENERON PHARMACEUTICALS, INC. (REGN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $59.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $59.10M, a 68.58% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $188.10M, a 489.66% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $31.90M, a 9.12% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $35.10M, a 17450.00% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2025-12-31 | $59.10M 10-K · filed 2026-02-04 |
| 2024-12-31 | $188.10M 10-K · filed 2026-02-04 |
| 2023-12-31 | $31.90M 10-K · filed 2026-02-04 |
| 2022-12-31 | $35.10M 10-K · filed 2025-02-05 |
| 2021-12-31 | $200.00K 10-K · filed 2024-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |